GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
about
Optimal usage of the GnRH antagonists: a review of the literatureIndividualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practiceGnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review articleGonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech.GnRH Agonist Triggering of Ovulation Replacing hCG: A 30-Year-Old Revolution in IVF Practice Led by Rambam Health Care CampusPharmacokinetic, pharmacodynamic, and clinical aspects of ovulation induction agents: A review of the literatureImpact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled TrialPreserving fertility in patients undergoing treatment for breast cancer: current perspectives.Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.Pharmaceutical options for triggering of final oocyte maturation in ARTRisk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.The Luteal Phase after GnRHa Trigger-Understanding An EnigmaEmpty follicle syndrome after GnRHa triggering versus hCG triggering in COS.GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study.Challenges and considerations in optimizing ovarian stimulation protocols in oncofertility patients.Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial.Efficacy of random-start controlled ovarian stimulation in cancer patientsGnRH agonist vs. hCG for triggering of ovulation--differential effects on gene expression in human granulosa cells.New algorithm for OHSS preventionOvarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist surveyEarly onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxisUse of gonadotropin-releasing hormone agonist trigger during in vitro fertilization is associated with similar endocrine profiles and oocyte measures in women with and without polycystic ovary syndrome.Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trialGnRH analogues in the prevention of ovarian hyperstimulation syndromeEvaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study.PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndromeCorifollitropin stimulation in combination with GnRH-antagonists after estradiol valerate pre-treatment. A pilot study on patientfriendly IVF.Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial.A Two-Pathway Mathematical Model of the LH Response to GnRH that Predicts Self-PrimingImpact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study.Pregnancies beyond the human biological fecundity.Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.The risks and outcome of pregnancy in an advanced maternal age in oocyte donation cycles.
P2860
Q21245566-9D094B02-B18C-412C-8D69-D8C817F7B766Q26829747-7F1D09E1-2179-4424-BB9F-A42408971FECQ28077044-7D38875B-EF17-46EC-9DB6-4937029865B4Q30796722-8AB2D87E-786C-4163-9C96-A37236471287Q33633426-D1FC8662-7638-4C11-8D86-70D8CC6C7B30Q33743109-3DAE2A44-47D3-423D-AC1F-3E97B8E858B5Q33799681-FC9569D4-8B17-4636-AEF4-2DCF327FCDC9Q33939688-57045A6F-0E49-4ADE-9A78-027811C107C9Q33944146-756262E4-DD65-49F9-B9F7-B3F61CFBB9B5Q34009789-F7612B11-5C74-46AC-8EB9-9EB6B592D483Q34428728-C977CD33-E014-499E-8C6B-6FB497007134Q34458877-EBFBFB8C-EAA6-4034-93A2-B6108FD8D704Q34635046-ACFF41DD-12FC-45E3-9ADA-FAE98CA426F6Q34636679-D66C37A0-9E6E-4281-94A1-AE170CC0FB0AQ34637134-445749B7-EFFE-4BE8-8C8A-F7F10D2326C2Q34866439-1B1A3730-83A8-4AE2-BACD-2E32F4AB174AQ35089325-50C6CF52-CD19-4120-AFD4-1FF9A009A0F2Q35112937-78696FFB-ADB5-450F-A42C-99AF85C9436EQ35591046-69F987D3-3BF0-4C22-95AD-980BA30748D7Q35769428-361F8F15-A01F-4DA7-B151-20FB8D87CD3CQ35938164-64B5F58F-2886-4E66-BE32-31F8649D9A5BQ36112513-CE7494E3-5E04-449C-9CCB-B921C4898891Q36193975-45D6CB3F-46D8-485C-BB83-57DF07E4F083Q36235804-54182DD2-3523-4828-A40D-A1CE7439116BQ36301761-469173D2-F390-4409-A66E-6CBB21127724Q36319447-6D182D02-2219-467E-B1C4-BB474F341704Q36358138-FAADE1D8-2BE2-4E9C-A286-3F7CBD36D19DQ36406595-2E4E9147-BECC-45F1-9E28-3820DD317BABQ36900329-8F2148C7-EC1F-4F2E-98E1-7FFD3B1893ADQ36952561-5DEDADBD-9BC7-44DF-AFDF-4078D061F236Q36957480-3A826303-8CAD-47F3-8DB9-650343878501Q37024897-A35F48AB-63B3-42BE-8B0A-2F1D906638B6Q37179427-60362E99-95BB-4385-98DD-47FEA291D0D9Q37326952-CDF9B4A5-3845-4DA1-A7C7-49D767BE9F35Q37350477-8F5BFCA3-0AF9-4606-B7FD-F5128E1803B8Q37351637-BA886357-8287-49F5-B28B-D061A34AF568Q37425142-DF3721F5-4F45-447E-A751-1E5CACF407D8Q37968646-44DA00B1-A5D4-460D-BE56-0488EE577298Q38053144-96A087E5-0C62-49CB-A067-72D309C9E00DQ38168281-12E66CA6-4393-42DA-A30C-A16DBF4B31C1
P2860
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@ast
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@en
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@nl
type
label
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@ast
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@en
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@nl
prefLabel
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@ast
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@en
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@nl
P2860
P3181
P356
P1476
GnRH agonist for triggering of final oocyte maturation: time for a change of practice?
@en
P2093
E G Papanikolaou
P2860
P304
P3181
P356
10.1093/HUMUPD/DMR008
P407
P577
2011-01-01T00:00:00Z